Biogipuzkoa
Centro de investigación
![Foto de Biogipuzkoa](/img/uploaded/BB680065D0326B877226AAACFBE7F51A.png)
![Foto de University of Lubeck](/img/noimage_org.png)
University of Lubeck
Lubeca, AlemaniaPublicaciones en colaboración con investigadores/as de University of Lubeck (45)
2024
-
Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease
Computers in Biology and Medicine, Vol. 176
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology
Alzheimer's and Dementia, Vol. 19, Núm. 3, pp. 807-820
-
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort
Movement Disorders, Vol. 38, Núm. 2, pp. 286-303
-
Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)
Nature
-
Genotype–Phenotype Correlations for ATX-TBP (SCA17): MDSGene Systematic Review
Movement Disorders, Vol. 38, Núm. 3, pp. 368-377
-
Genotype–phenotype relations for episodic ataxia genes: MDSGene systematic review
European Journal of Neurology, Vol. 30, Núm. 10, pp. 3377-3393
-
Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN-derived networks and highlights causal links in Alzheimer's disease
Alzheimer's and Dementia, Vol. 19, Núm. 8, pp. 3350-3364
-
Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning
Genome Medicine, Vol. 15, Núm. 1
-
Whole-exome rare-variant analysis of Alzheimer's disease and related biomarker traits
Alzheimer's and Dementia, Vol. 19, Núm. 6, pp. 2317-2331
2022
-
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease
Molecular neurodegeneration, Vol. 17, Núm. 1, pp. 27
-
Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (Molecular Neurodegeneration, (2022), 17, 1, (27), 10.1186/s13024-022-00521-3)
Molecular Neurodegeneration
-
Detailed stratified GWAS analysis for severe COVID-19 in four European populations
Human Molecular Genetics, Vol. 31, Núm. 23, pp. 3945-3966
-
Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 14, Núm. 1
-
Genetically Determined Reproductive Aging and Coronary Heart Disease: A Bidirectional 2-sample Mendelian Randomization
The Journal of clinical endocrinology and metabolism, Vol. 107, Núm. 7, pp. e2952-e2961
-
Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery Dataset
Frontiers in Aging Neuroscience, Vol. 14
-
Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
Acta Neuropathologica, Vol. 144, Núm. 5, pp. 821-842
-
Predicting AT(N) pathologies in Alzheimer’s disease from blood-based proteomic data using neural networks
Frontiers in Aging Neuroscience, Vol. 14
-
Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation
Molecular Psychiatry, Vol. 27, Núm. 4, pp. 1990-1999
2021
-
Csf proteomic alzheimer’s disease-predictive subtypes in cognitively intact amyloid negative individuals
Proteomes, Vol. 9, Núm. 3